The results showed that the combined treatment inhibited the expression of cyclin-dependent kinase 2 (CDK2) at the mRNA level (p < 0.05) in both pan-cancer cell lines (Figure 7A–C and Figure S9A–D). This evidence concerns the gene CDK2 and cancer.